Rakovina Therapeutics to Present New Data at the AACR Annual Meeting 2026 - World's Premier Cancer Research Forum

Executive Summary

• Rakovina Therapeutics announced that two research abstracts will be presented at the 2026 AAC & R Annual Meeting in San Diego.
• The first abstract details a novel brain‑penetrant dual ATR‑mTOR inhibitor designed with the Enki™ AI platform for PTEN‑deficient cancers.
• The second abstract describes a lipid nanoparticle formulation of the bifunctional PARP/HDAC inhibitor Kt‑3283, created using the EnsaliX AI platform and NanoPalm collaboration.

Key Details

• Abstract 1 – Dual ATR‑mTOR Inhibitor
• Title: “A novel brain‑penetrant dual ATR‑mTOR inhibitor for PTEN‑deficient cancers.”
• Session: DNA Damage and Repair 2 (Experimental and Molecular Therapeutics).
• Date/Time: April 20, 2026, 9:00 AM – 12:00 PM; Abstract No. 5034.
• Technology: Enki™ generative AI platform + Variational AI collaboration.

• Target indication: PTEN‑deficient gliomas and breast cancers (up to 40% of gliomas, up to 63% of breast cancers).

• Abstract 2 – Lipid Nanoparticle Formulation of Kt‑3283

• Title: “Development of a lipid nanoparticle formulation of the bifunctional PARP and HDAC inhibitor kt‑3283.”
• Session: Drug Delivery (Chemistry).
• Date/Time: April 21, 2026, 2:00 PM – 5:00 PM; Abstract No. 4665.
• Technology: EnsaliX AI platform + NanoPalm partnership (Riyadh, Saudi Arabia).

• Goal: Improve encapsulation efficiency, cellular uptake, and pharmacological performance of Kt‑3283 for clinical translation.

• Company Statements

• CEO Kim Oishi highlighted the significance of presenting two abstracts for the second consecutive year and emphasized AI’s role in accelerating cancer drug development.

• President & CSO Dr. Mads Daugaard noted the complementary nature of the two programs—enhanced delivery of an existing bifunctional compound and creation of new brain‑penetrant inhibitors.

• Strategic Context

• Rakovina’s preclinical pipeline targets DNA‑damage response vulnerabilities present in up to 75% of solid tumors, focusing on hard‑to‑treat cancers (breast, ovarian, prostate, brain).
• Near‑term milestones include: in‑vivo testing of LNP formulations under the kt‑3000 program, progression of a lead candidate in the kt‑5000AI program, and initiation of pharmaceutical partnership discussions as data mature.

Notable Quotes

• “We are thrilled that for the second year in a row, we are presenting two abstracts at the AACR Annual Meeting… We are using AI to solve problems that have held back cancer drug development for years.” – Kim Oishi, CEO
• “What makes these two programs particularly exciting is that they address cancer from two distinct but complementary angles… one focused on smarter delivery of a proven bifunctional compound, and one on designing entirely new molecules to reach tumors that current therapies simply cannot access.” – Dr. Mads Daugaard, President & CSO